Trial Profile
Real Life Dosing Regimen of Remicade in Austria in Crohn's Disease - Program Extension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 25 Oct 2011 Actual patient number is 348 as reported by ClinicalTrials.gov.
- 09 Sep 2010 Actual end date Jul 2010 added as reported by ClinicalTrials.gov.
- 09 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.